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Purpose: To investigate the temporal interrelationship between depression severity, cogni-
tive symptoms, and functioning in patients with major depressive disorder (MDD) in the
PERFORM study (NCT01427439).
Patients and methods: PERFORM was a 2-year, multicenter, prospective, noninterven-
tional cohort study in outpatients with MDD who were either initiating antidepressant
monotherapy or undergoing their first switch of antidepressant. Patients were enrolled by a
general practitioner or psychiatrist. Structural equation model (SEM) analysis was used to
explore temporal associations between patient-reported depression severity (9-item Patient
Health Questionnaire score), cognitive symptoms (5-item Perceived Deficits Questionnaire
score), and functional impairment (Sheehan Disability Scale total score). Standardized
regression coefficients (SRCs) were used to evaluate the relationship between each outcome
and scores from the most recent prior visit over the 2 years of follow-up.
Results: Between February 25, 2011, and February 19, 2015, 1,159 eligible patients with MDD
completed the baseline and ≥1 follow-up visit at 194 sites in five European countries (France,
Germany, Spain, Sweden, and the UK). Overall, 1,090 patients had assessments for ≥1 outcome
measure at two consecutive visits. Severity of cognitive symptoms at baseline and Months 2 and
18 predicted functional impairment at Months 2, 6, and 24, respectively (SRC: 0.18, 0.15, and
0.22; P<0.001). Depression severity at Months 2, 6, and 12 predicted functional impairment at
Months 6, 12, and 18, respectively (SRC: 0.17, 0.25, and 0.22; P<0.001). Severity of cognitive
symptoms at baseline and Month 18 predicted depression severity at Months 2 and 24, respec-
tively (SRC: 0.19 and 0.22; P<0.001). Functional impairment did not significantly predict the
severity of depression or cognitive symptoms, and depression severity did not significantly
predict the severity of cognitive symptoms at any time point.
Conclusion: Patient-reported severity of cognitive symptoms appears to be an independent
and significant determinant of subsequent functional impairment and depression severity in
patients with MDD.
Keywords: major depressive disorder, cognitive symptoms, functional impairment,
structural equation model
Introduction
Major depressive disorder (MDD) is a common and debilitating condition that affects
more than 120 million people worldwide.1 MDD is characterized by emotional,
physical, and cognitive symptoms that significantly affect patient functioning.2
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Compared with the general population, patients with MDD
report substantial deficits in family, work, and social
functioning.3–8 Functional impairment imposes a significant
burden in MDD.9–12 Assessment of functional impairment
in patients with MDD provides important information on
disease impact and remission from the patient’s own per-
spective. Functional recovery should be considered an
important treatment goal if patients are to return to produc-
tive and fulfilling daily lives.8,13,14
Functional impairment has been shown to persist even
after remission of mood symptoms in patients with
MDD,6,15–18 preventing a full return to social and profes-
sional life. In a large US study designed to assess the efficacy
of sequential acute treatments for MDD (Sequenced
Treatment Alternatives to Relieve Depression [STAR*D]),
only 7% of patients reported within-normal functioning
before initiation of antidepressant therapy.6 In STAR*D,
patients who achieved remission of depressive symptoms
showed greatest improvement in functional impairment;
however, 20–40% of these remitted patients continued to
experience ongoing deficits in functioning.6 Residual func-
tional impairment following remission of depressive symp-
toms has also been shown to be a predictor of subsequent
relapse in patients with MDD.19 This lack of synchronicity
between symptomatic improvement and functioning high-
lights an unmet clinical need in patients with MDD.8
Cognitive symptoms, such as disturbances in attention,
memory, processing speed and executive functioning, are a
core feature of MDD that are gaining attention as a major
contributor to disease burden and an appropriate concomi-
tant treatment target.7,14,20–23 Indeed, addressing cognitive
symptoms of MDD may be necessary to achieve func-
tional recovery. Systematic reviews have concluded that
there is evidence for an association between cognitive
functioning and functional impairment in individuals
with MDD, but that the quality of evidence is weak and
the evidence for a causal link is limited.21,24
Recent real-world evidence suggests an association
between cognitive symptoms and functional impairment in
patients with MDD, independent of the severity of
depression.25 These data stem from the PERFORM
(Prospective Epidemiological Research on Functioning
Outcomes Related to Major depressive disorder) study,
which was a European prospective observational cohort
study undertaken to better understand the course of a
depressive episode and its impact on patient functioning
over a 2-year period in outpatients with MDD who were
either initiating or undergoing their first switch of
antidepressant monotherapy.25 Functional impairment in
this population was not only associated with severity of
depressive symptoms, but also with severity of cognitive
symptoms consistently throughout the 2 years of follow-up.
However, the time-dependent interrelationships between
severity of depressive symptoms, cognitive symptoms, and
functional impairment in patients with MDD remain to be
fully elucidated. In particular, it is not known which, if any,
of these factors precede the others and whether the causal
relationships between these factors change over time.
This analysis was undertaken to further investigate the
interrelationship of depression severity, cognitive symp-
toms, and functioning in patients treated for MDD in the
PERFORM study using the structural equation model
(SEM) approach.26 This statistical method allows for
simultaneous estimation of associations between groups
of variables, permitting elucidation of the time dependency
of changes and potential causal relationships. This analysis
aims to provide further insight into the role of cognitive
symptoms in patients with MDD and the potential impact
of these cognitive symptoms in terms of depression sever-
ity and functional impairment.
Methods
Study design
PERFORM comprised a 2-year, prospective, multicenter,
noninterventional cohort study in outpatients with MDD
who were enrolled by either a psychiatrist or a general
practitioner (GP) at 194 clinical sites in five European
countries (France, Germany, Spain, Sweden, and the UK)
(NCT01427439). Study design and inclusion/exclusion
criteria have been reported in detail previously.25,27 In
brief, study participants were 18–65 years of age, were
clinically diagnosed with MDD (Diagnostic and Statistical
Manual of Mental Disorders 4th Edition, Text Revision
criteria; confirmed by the Mini International Psychiatric
Interview questionnaire [depression module]), and were
either starting antidepressant monotherapy or switching
antidepressant for the first time. The treating physician
determined which antidepressant was prescribed, and the
decision was not influenced by study participation.
Ethical approval and consent to
participate
Ethical approval was obtained from the necessary authorities
for each study site in accordance with national regulations
regarding observational studies (see Supplementary
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Appendix 1). The study was conducted in accordance with
the Declaration of Helsinki. All patients provided written
informed consent to participate in the study.
Study assessments
Study assessments were conducted at patients’ routine
clinic visits at baseline and 2, 6, 12, 18, and 24 months.
Patients assessed their depression severity using the 9-item
Patient Health Questionnaire (PHQ-9);28 cognitive symp-
toms using the 5-item Perceived Deficit Questionnaire
(PDQ-5);29,30 and functional impairment using the
Sheehan Disability Scale (SDS).31,32 In this analysis,
SDS total scores were included only if patients reported
scores in all three domains. Further information on each of
these scales can be found in Supplementary Appendix 2.
Statistical analysis
The population for each structural equation comprised all
patients who met the study inclusion criteria and provided
data for the parameters at the appropriate time points.
Descriptive summary statistics are shown for the three
outcomes of interest by time point.
The SEM approach was used to explore the temporal
association between PHQ-9, PDQ-5, and SDS total score.26
An SEM is a series of multivariate linear regressions mod-
eled in a single analysis. Figure 1A shows all the effects that
were estimated in the SEM; the three outcomemeasures were
allowed to depend on the scores of all outcomes at the most
recent prior visit, but not at any earlier visits. Outcome
measures from the same visit were allowed to be correlated.
Each of the three outcome measures was assessed at
five post-baseline time points. A joint model for the 15
post-baseline measurements was estimated by full infor-
mation maximum likelihood (FIML) in R (version 3.3.1)
using the “lavaan” package (version 0.5–20).33 FIML pro-
duces unbiased parameter estimates when data are missing
at random. For model evaluation, the root mean square
error of approximation (RMSEA; good fit generally
accepted as <0.08) and comparative fit index (CFI; good
fit generally accepted as >0.95) were used, while chi-
squared tests were used to evaluate the statistical signifi-
cance of specific parameters in the model. Standardized
regression coefficients (SRCs) were reported to facilitate
direct comparison of effect size between PHQ-9, SDS, and
PDQ-5 scores at the different time points.
As well as the model using SDS total score, similar
models were fitted with each of the three SDS subscales in
three separate SEM analyses to explore consistency across
the different functionality items and to explore whether
results were mainly driven by one or two of the subscales.
Alternative and more complex SEMs that also included
effects of scores earlier than the prior time point were used
to explore longer dependences in the trajectories of the
three patient-reported outcomes.
G-computation was used as a sensitivity analysis.34–36
This method provides estimates with causal interpretations
from nonrandomized data under certain conditions, such as
when unmeasured confounders may be present (Figure 1B).
InG-computation, confounding effects are removed by creat-
ing new datasets of counterfactuals, where the “exposure” is
uncorrelated with the potential confounders and then estimat-
ing the mean difference between two different exposures.
Further details of the G-computation methodology are pro-
vided in Supplementary Appendix 3.
In this analysis, P-values were not corrected for multi-
ple comparisons and should be considered nominal.
Results
Study population
A total of 1,895 patients were screened for inclusion in the
PERFORM study, 1,402 of whom met all study inclusion/
exclusion criteria and were enrolled. The first patient was
screened on February 25, 2011, and the last patient com-
pleted the study on February 19, 2015. A total of 1,159
patients who completed the baseline visit with at least one
follow-up visit without any violation of inclusion or exclu-
sion criteria were included in this analysis. The study
population has been described in detail previously.25,27
Baseline demographic and clinical characteristics are
shown in Table S1. In brief, most patients were enrolled
and followed up by GPs (83.6%), 56.6% had experienced
a previous depressive episode, 78.7% were initiating anti-
depressant therapy, and 21.3% were switching antidepres-
sant therapy for the first time. The main reasons for
switching were lack of efficacy (77.3%), adverse events
(9.3%), patient decision (6.9%), and lack of compliance
(3.2%). The most frequent antidepressants prescribed at
the initial study visit were citalopram (24.0%), escitalo-
pram (20.2%), fluoxetine (10.5%), sertraline (9.5%), and
duloxetine (9.0%); all other antidepressants were used in less
than 5% of patients. Mean (SD) age was 44.3 (12.0) years
and 73.2% of patients were female.
A total of 1,090 patients (94% of the study population)
had assessments for at least one outcome measure at two
consecutive visits. Summary characteristics of the three
Dovepress Haro et al
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patient-reported outcomes of interest at the six time points
over the 2 years of follow-up are shown in Table 1 and
Figure 2. As shown, there were more patients with a PHQ-
9 score and fewer with an SDS score than with a PDQ-5
score at all time points (Table 1). A gradual decrease in
mean scores over time was seen for all three outcome
measures (Figure 2), suggesting general improvement in
depressive symptoms, cognitive symptoms, and function-
ing over the 2 years of follow-up. A slower rate of change
was observed for cognitive symptoms (PDQ-5 score) than
for the other outcomes; however, no formal statistical
comparisons were performed.
The number of patients included in the SEM and the
G-computation analyses ranged from 207 to 446.
Relationship between depression severity,
cognitive symptoms, and functional
impairment (SEM analysis)
The fit of the SEM produced a CFI of 0.941 and RMSEA of
0.077, suggesting an acceptable (CFI) or good (RMSEA) fit
of the model. More complex models were explored with
more dependencies on earlier time points. These models
produced marginally better fits of the data according to the
fit indices; however, relationships between outcomes at the
consecutive visits were considered to be most relevant in
terms of potential implications for routine practice.
Figure 3 shows paths that were statistically significant
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Figure 1 Illustration of the (A) saturated structural equation model (SEM) and (B) G-computation model.
Notes: (A) The SEM estimates all regression coefficients between 5-item Perceived Deficit Questionnaire (PDQ-5) score, Sheehan Disability Scale (SDS) total score, and
9-item Patient Health Questionnaire (PHQ-9) score at subsequent visits (solid one-headed arrows), as well as variances and covariances between PDQ-5 score, SDS total
score, and PHQ-9 score at the same visits (dotted double-headed arrows), in a single analysis. (B) In the G-computation of the causal effect of PDQ-5 score at Month 2 on
SDS total score at Month 6 (example highlighted in gray box), SDS total score and PHQ-9 score at Month 2 are potential confounders and are therefore accounted for,
whereas PDQ-5 and PHQ-9 scores at Month 6 are mediating variables and are therefore not accounted for.
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path is proportional to its standardized effect size. The
strict confidence level of 0.001 in the SEM analysis is
chosen to disregard statistically significant effects that
likely have no clinical importance. As expected, patient-
rated depression severity (PHQ-9 score), functional
impairment (SDS total score), and cognitive symptoms
(PDQ-5 score) depended moderately to strongly on the
value of the previous assessment on the same scale at
Table 1 Summary statistics of PDQ-5 score, SDS total score, and PHQ-9 score by visit
Variable Baseline Month 2 Month 6 Month 12 Month 18 Month 24
PDQ-5 N 770 714 644 654 580 564
Mean (SD) 11.38 (4.57) 10.32 (4.77) 9.03 (5.08) 8.23 (5.18) 8.03 (5.23) 7.81 (5.19)
Median [Q1, Q3] 12 [8, 15] 11 [7, 14] 5 [5, 13] 8 [4, 12] 8 [4, 12] 8 [3, 12]
SDS total N 750 607 586 554 486 458
Mean (SD) 19.19 (6.76) 14.71 (7.94) 11.86 (8.67) 10.30 (8.20) 9.91 (8.51) 9.25 (8.13)
Median [Q1, Q3] 20 [15, 24] 15 [9, 21] 12 [4, 18] 9 [3, 16] 8 [2, 16] 7.5 [2, 15]
PHQ-9 N 940 805 740 701 638 604
Mean (SD) 17.61 (5.31) 12.73 (6.24) 10.76 (6.65) 9.85 (6.79) 9.62 (6.86) 9.11 (6.60)
Median [Q1, Q3] 18 [14, 22] 13 [8, 17] 10 [5, 15] 9 [4, 14] 9 [4, 14] 8 [4, 13]
Abbreviations: PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; SD, standard deviation; SDS, Sheehan Disability Scale;
Q, quartile.
Figure 2 Distribution of depression severity (9-item Patient Health Questionnaire [PHQ-9] score, range 0–27), functional impairment (Sheehan Disability Scale [SDS] total
score, range 0–30) and cognitive symptoms (5-item Perceived Deficit Questionnaire [PDQ-5] score, range 0–20) by visit.
Note: Higher scores indicate worse outcomes.
Dovepress Haro et al
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each time point over the 2 years of follow-up, with SRCs
of 0.37–0.71 for PHQ-9, 0.44–0.50 for SDS total score,
and 0.60–0.84 for PDQ-5 (Table S2). Depression severity
at Months 2, 6, and 12 predicted the degree of functional
impairment at Months 6, 12, and 18, respectively (SRC:
0.17, 0.25, and 0.22). Severity of cognitive symptoms at
baseline, Month 2, and Month 18 predicted the degree of
functional impairment at Months 2, 6, and 24, respectively
(SRC: 0.18, 0.15, and 0.22). Severity of cognitive symp-
toms at baseline and Month 18 also predicted depression
severity at Months 2 and 24, respectively (SRC: 0.19 and
0.22). However, the degree of functional impairment did
not predict depression severity or the severity of cognitive
symptoms at the P<0.001 level at the subsequent visit at
any time point. Similarly, depression severity did not
predict the severity of cognitive symptoms at the
P<0.001 level at the subsequent visit at any time point.
The SEM analysis was repeated, substituting each of
the three SDS subscale scores for the SDS total score.
There were no notable differences between the three ana-
lyses, and no ambiguities were observed between the
analysis using the SDS total score and the analyses based
on the individual subscales (data not shown).
Figure 4 provides a graphical representation of the stan-
dardized effects based on the G-computation, including
effects that were significant at the P<0.05 level; the thick-
ness of each effect is proportional to its standardized effect
size. Results of the G-computation generally confirmed
those of the SEM analysis. Depression severity at Months
2, 6, and 12 predicted the degree of functional impairment
PHQ-9 PHQ-9 PHQ-9 PHQ-9 PHQ-9 PHQ-9
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Figure 3 Significant regression coefficients based on the structural equation model standardized by time point.
Note: Only effects that were significant at the P<0.001 level are shown; the thickness of the arrows is proportional to the effect estimates.
Abbreviations: PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; SDS, Sheehan Disability Scale.
PHQ-9 PHQ-9 PHQ-9 PHQ-9 PHQ-9 PHQ-9













Baseline Month 2 Month 6 Month 12 Month 18 Month 24
Figure 4 Causal effect sizes from G-computation standardized by time point.
Note: Effects that were significant at the P<0.001 level are shown in black, and effects that were significant at the P<0.05 level (but not at the 0.001 level) are shown in gray;
the thickness of the arrows is proportional to the effect estimates.
Abbreviations: PDQ-5, 5-item Perceived Deficit Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; SDS, Sheehan Disability Scale.
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at Months 6, 12, and 18, respectively (SRC: 0.19, 0.30, and
0.26). Severity of cognitive symptoms at baseline and
Month 18 predicted the degree of functional impairment at
Months 2 and 24, respectively (SRC: 0.15 and 0.21). The
severity of cognitive symptoms at baseline and Month 18
predicted depression severity at Months 2 and 24, respec-
tively (SRC: 0.19 and 0.21). As in the SEM analysis, the
degree of functional impairment did not predict depression
severity or the severity of cognitive symptoms at the sub-
sequent visit at any time point, and depression severity did
not predict the severity of cognitive symptoms at the sub-
sequent visit at any time point.
Figure S1 shows the SRCs from the SEM plotted
against the G-computed effect estimates. No systematic
differences were observed between estimates based on the
two approaches, suggesting robustness of the findings. In
general, the standard errors were 40–70% greater for the
G-computed estimates (data not shown), owing partly to the
complexity of the SEM that modeled 15 variables simulta-
neously. This is reflected in the fact that fewer effects were
statistically significant using G-computation compared with
the SEM. Nevertheless, the two methods were in excellent
agreement, and all effects that were statistically significant
at the P<0.05 level in the G-computation were statistically
significant at the P<0.001 level in the SEM.
Discussion
This analysis of data from the PERFORM study shows
that severity of cognitive symptoms is an important deter-
minant of both subsequent functional impairment and
depression severity throughout the 2 years of follow-up,
but particularly at baseline and at later time points. These
results are in keeping with previous findings concerning
the potential impact of cognitive symptoms on functioning
and health-related quality of life in patients with
MDD,25,37–41 and also highlight the influence of cognitive
symptoms on the course of mood symptoms in this popu-
lation. As expected, the results of this analysis also show
that depression severity is a major determinant of func-
tional impairment in patients with MDD, which is consis-
tent with the results of previous studies.7,20,25,42–44 In
contrast, functional impairment was not found to predict
the severity of depression or cognitive symptoms at any
subsequent visit. Similarly, depression severity did not
predict cognitive symptoms at any subsequent visit.
These findings highlight the impact of cognitive symptoms
on functioning in patients with MDD. The results of the
SEM analysis based on total SDS score were confirmed in
separate analyses for each of the three SDS functioning
subscales and using G-computation in a causal inference
model as a sensitivity analysis, suggesting robustness of
the findings and implying a causal relationship between
both depressive and cognitive symptoms and everyday
functioning in patients with MDD.
It is well documented that functional impairment can per-
sist in patients with MDD even after remission of mood
symptoms.6,15–18 Other studies have shown cognitive symp-
toms to persist longer than depressive symptoms in MDD and
that these residual cognitive symptoms can persist even in
patients who achieve clinical remission.23,45,46 In the
PERFORM study, residual perceived cognitive symptoms in
patients who achieved remission of depression at Month 2
were also found to be associated with an increased risk of
relapse at Month 6.47 Collectively, these findings indicate that
cognitive symptoms are an important and independent treat-
ment target in patients with MDD and suggest that treatment
interventions targeting both initial and residual cognitive
symptomsmay improve functional recovery in this population,
both directly and/or via improvement of clinical outcomes.
Functional recovery is critical for patients withMDD to enable
them to return to productive and fulfilling daily lives.8,13,14
Both pharmacological and nonpharmacological antide-
pressant treatments may improve cognitive symptoms to
some extent when improving mood symptoms; however, to
date, only vortioxetine has been shown to have robust and
direct effects on cognitive function.48,49 In a recent interven-
tional, open-label, real-world Canadian study undertaken to
examine the association between patient-reported cognitive
symptoms and workplace productivity in working patients
with MDD treated with vortioxetine (Assessment in Work
productivity and the Relationship with Cognitive symptoms
[AtWoRC] study), a highly significant positive correlation
was seen between improvements in cognitive symptoms and
improvements in functioning and workplace productivity
after 12 and 52 weeks of vortioxetine treatment.50,51 As in
the present study, SEM analyses confirmed that improve-
ments in cognitive symptoms predicted long-term improve-
ments in functional outcomes even after adjusting for
severity of depressive symptoms.51
Amajor strength of this study is that it was performed in a
real-world setting with long-term longitudinal follow-up of a
large cohort of patients, most of whom were enrolled and
followed up by GPs. Study sites were balanced with the
national proportions of these clinicians treating patients
with depression to ensure findings were applicable to routine
practice. All outcome measures were self-reported and
Dovepress Haro et al
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therefore represent disease severity and impact from the
patient’s own perspective, which appears particularly valid
in patients with mental health disorders such as MDD.52
Although the use of objective measures can provide impor-
tant information for the clinician, use of patient-reported
outcomes is in keeping with awareness of the limitations of
clinical symptom-based measures in assessing recovery from
mental illness in a way that is meaningful to patients.53–55
Furthermore, it has recently been reiterated that while both
objective measures of cognitive function and subjectively
rated cognitive symptoms may be clinically relevant, the
overlap and correlation between the two approaches are
limited.50,51,56 In this study, cognitive symptoms were
assessed using the PDQ-5. Despite depression often being
associated with cognitive symptoms, there is limited aware-
ness for recognition and assessment of cognitive symptoms
in patients with MDD during routine care. The PDQ was
initially developed in order to provide a self-report measure
of cognitive dysfunction in patients with multiple
sclerosis.29,30 The PDQ scores of patients with multiple
sclerosis have been found to be correlated with scores on
depression scales, but not with neuropsychological test
scores.57 In addition, the antidepressants vortioxetine and
duloxetine have demonstrated significant improvements in
PDQ scores relative to placebo.58 The results of the present
study suggest that self-perceived cognitive symptoms are
more relevant in patients with depression than objective
measures of cognitive function. The full-length PDQ consists
of 20 items;29,30,59 the abbreviated 5-item version was used
in this study because it is more convenient to administer in
routine practice settings. Indeed, use of neuropsychological
tests to assess cognitive function is limited by a lack of
availability and time constraints in general practice.
Considering the length of the study, the decrease over time
in the number of patients reporting the outcomes of interest
wasmodest. The long duration of study also enables character-
ization of long-term functional outcomes, which may lag
behind improvements on other measures, such as depressive
symptoms. In terms of themethodology used, the SEMuses all
the repeatedmeasures of the three variables at all time points in
a singlemodel, allowing evaluation of all the potential associa-
tions at the same time instead of focusing on each time point
and direction in separate models. By simultaneously taking a
range of associations into account, the significant predictions
of long-term functional outcomes found in the present analysis
can be regarded as being independent of changes in other
symptomdomains.Direct adjustments for the impact of factors
such as illness duration, type of antidepressant, educational
level, etc.were notmade in the SEMbecause the analyseswere
adjusted for the immediately preceding SDS, PHQ-9, and
PDQ-5 outcomes, which would reflect any effect of other
factors. Only a potential interaction between these factors and
SDS, PHQ-9, or PDQ-5 remained unadjusted. Such an inter-
action would imply that one of the factors has a different
impact on SDS, PHQ-9, and PDQ-5 outcomes at different
time points; however, this is unlikely to be the case for most
of the factors. The agreement between the results of the SEM
and theG-computation, which controls for potential confound-
ing factors, supports the robustness of our findings.
A potential limitation is that the study recruited only
outpatients who were initiating antidepressant monother-
apy or switching antidepressant monotherapy for the first
time, which may somewhat limit generalization of the
study findings. The potential for negative response bias
in patients with depression when completing self-report
scales must also be recognized. Furthermore, as one of
the SDS subscores was not completed by patients who did
not work or study for reasons unrelated to the disorder,
analyses of SDS total scores are limited to patients who
provided scores for all three SDS domains, ie, to the
working population only. Regarding the statistical metho-
dology used, more complex SEMs that explored depen-
dencies between the three outcomes from earlier time
points than the immediately prior visit generally produced
better fit of the data according to the fit indices, but at the
expense of clear clinical interpretation and relevance. In
terms of clinical utility, it is reasonable to assume that the
relationships between depression severity or cognitive
symptoms and functioning at the subsequent visit are the
most appropriate in terms of relevance for routine practice.
In summary, beyond confirming that depression sever-
ity is a major predictor of functional impairment in MDD,
this analysis shows that the severity of patient-reported
cognitive symptoms is also an independent and important
predictor of later functional impairment and generally
predicts depression severity at subsequent clinic visits.
These findings highlight the importance of recognizing
cognitive symptoms in patients with MDD in daily prac-
tice and suggest that treatment interventions targeting
emotional, physical, and cognitive symptoms could
improve functional recovery in this population.
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